Innoviva Market Cap 2010-2024 | INVA

Innoviva market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of February 21, 2025 is $1.13B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.131B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $827.866B 67.16
Johnson & Johnson (JNJ) United States $384.448B 15.98
Novo Nordisk (NVO) Denmark $375.786B 25.45
AbbVie (ABBV) United States $354.625B 19.85
Roche Holding AG (RHHBY) Switzerland $262.452B 0.00
Merck (MRK) United States $221.798B 11.48
Novartis AG (NVS) Switzerland $219.342B 13.74
Pfizer (PFE) United States $146.775B 8.33
Sanofi (SNY) $137.374B 13.01
Bayer (BAYRY) Germany $22.556B 3.61